La vendita allo scoperto per Eli Lilly dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Eli Lilly. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Eli Lilly (NYSE:LLY) Azioni, Report sulle vendite allo scoperto

Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co

Eli Lilly  shutterstock_664142593

Biotech

Equities

News

Health Care

Risultati sorprendenti e prospettive future: l&#39;evoluzione dei trattamenti per la perdita di peso sotto la lente degli esperti.

Obesità e farmaci innovativi: cosa rivelano le nuove sperimentazioni?

Pharmacist,Holding,1,Tablets,(single,Dose,),Of,Contraceptive,Pill

Earnings

Markets

Il colosso farmaceutico danese ha richiesto l&#39;approvazione della FDA per una formulazione orale del suo farmaco anti-obesità di successo.

Novo Nordisk presenta &#34;Wegovy in pillola&#34;: rivoluzione per i farmaci dimagranti

Price Target

Pre-Market Outlook

Analyst Ratings

Trading Ideas

Prima della pubblicazione dei dati trimestrali, si delineano scenari e attese contrastanti tra gli osservatori finanziari più attenti.

Eli Lilly: cosa dice il mercato prima della trimestrale? L&#39;analisi degli esperti

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live Group

LIBERTY LIVE SERIES B by Liberty Media Corporation

Liberty Media Corporation - Series C Liberty Live Common Stock

Tidal Trust II Defiance Daily Target 2X Long LLY ETF

<figure class="wp-block-image aligncenter size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081653/Top-Image-1024x683.png" alt="" class="wp-image-13068" style="width:920px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081653/Top-Image-1024x683.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081653/Top-Image-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081653/Top-Image-768x512.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081653/Top-Image.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">A Threat To The Diabetes Cash Cow</h2>
Years ago, in a conversation with an endocrinologist, I mentioned there was no incentive to cure diabetes, giving the money companies were making from managing it (with testing supplies, insulin, etc.). He replied that the incumbents had no incentive to cure it, but a startup company would. Now it looks like one has—at least in one patient. Sana Biotechnology, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) has developed a one-time treatment that could upend the entire diabetes industry.
<h2 class="wp-block-heading">How It Works</h2>
Type 1 diabetes occurs when the immune system destroys the pancreatic beta cells, which are responsible for producing insulin. While transplants of donor islets—clusters of cells that include beta cells—can restore insulin production, they require scarce donor tissue and lifelong immunosuppressive drugs, which carry serious risks. As a result, insulin remains the only practical treatment for nearly all Type 1 diabetics.&nbsp;Sana has successfully engineered donor-derived islets to evade immune rejection, enabling a Type 1 diabetic to produce his own insulin, without the need for immunosuppressive drugs.
This isn't just theory. In a clinical trial at Uppsala University in Sweden, Sana's genetically engineered pancreatic islets were injected into the forearm of a Type 1 diabetic. As the company noted in its annual report, this patient is now&nbsp;more than three months post-treatment, making his own insulin for the first time in 30 years—with no immunosuppressive therapy.
A recent presentation by Sana shows the results of this experiment so far. The C-peptide mentioned there is a biomarker of insulin production.
<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="578" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081738/Clinical-Results-1024x578.jpg" alt="" class="wp-image-13069" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081738/Clinical-Results-1024x578.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081738/Clinical-Results-300x169.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081738/Clinical-Results-768x433.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081738/Clinical-Results.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Slides from Sana's <a href="https://ir.sana.com/static-files/1f3a1d8c-24eb-4695-9380-747332ddae2a">May 2025 Corporate Presentation</a>.</figcaption></figure>
As the subsequent slide in the presentation shows, the patient was producing no insulin before the procedure, but has been producing insulin consistently since.
<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="580" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081849/C-Peptide-Slide-1024x580.jpg" alt="" class="wp-image-13070" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081849/C-Peptide-Slide-1024x580.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081849/C-Peptide-Slide-300x170.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081849/C-Peptide-Slide-768x435.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081849/C-Peptide-Slide.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">The Plan For Mass Production</h2>
The islet cells used in that trial came from a cadaveric donor. Sana's goal is to scale this breakthrough using&nbsp;stem cell–derived islets—which contain insulin-producing beta cells—that can be manufactured in large quantities and delivered off the shelf. The result would be a&nbsp;one-time treatment&nbsp;that could eliminate the need for insulin, blood sugar monitoring, and other diabetes therapies.
<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="575" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081940/One-time-treatment-1024x575.jpg" alt="" class="wp-image-13071" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081940/One-time-treatment-1024x575.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081940/One-time-treatment-300x169.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081940/One-time-treatment-768x431.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081940/One-time-treatment.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Larger dose‑escalation cohorts under way, with 6‑ and 12‑month read‑outs expected over the next year.
<h3 class="wp-block-heading">The Potential Market Impact</h3>
If the current results hold up, Sana's therapy would convert Type‑1 diabetes from a&nbsp;chronic drug‑and‑device market&nbsp;into a&nbsp;one‑time cell‑therapy market—a seismic shift for incumbents.
<figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="963" height="547" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082028/Market-Impact.png" alt="" class="wp-image-13072" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082028/Market-Impact.png 963w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082028/Market-Impact-300x170.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082028/Market-Impact-768x436.png 768w" sizes="(max-width: 963px) 100vw, 963px" /></figure>
As you can see above, diabetes therapies comprise 75% of Novo Nordisk A/S&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) sales and 43% of Ely Lilly and Company&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>). For DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) and Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>), diabetes is pretty much their entire businesses.
<h2 class="wp-block-heading">The Timeline That Matters</h2>
Some potential milestones to keep in mind for Sana headlines that could impact the diabetes therapy industry.
<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="527" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082137/Timeline-1024x527.png" alt="" class="wp-image-13073" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082137/Timeline-1024x527.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082137/Timeline-300x154.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082137/Timeline-768x395.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082137/Timeline.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">The Bottom Line</h2>
Sana has not&nbsp;cured&nbsp;diabetes yet—but a&nbsp;&gt; 3‑month insulin‑free human case without immunosuppression&nbsp;is more evidence than the market usually prices into chronically‑treated franchises. Shareholders of the incumbent companies mentioned above ought to consider hedging. The Portfolio Armor iPhone app can help you find the least expensive hedge that fits your risk tolerance and time frame. You can download it by aiming your iPhone camera at the QR code below (or by&nbsp;<a href="https://apps.apple.com/us/app/portfolio-armor/id394951144">tapping here</a>, if you are reading this on your iPhone).
<figure class="wp-block-image size-large"><a href="https://apps.apple.com/us/app/portfolio-armor/id394951144"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082314/PA-JPEG-5-1024x683.jpeg" alt="" class="wp-image-13074" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082314/PA-JPEG-5-1024x683.jpeg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082314/PA-JPEG-5-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082314/PA-JPEG-5-768x512.jpeg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082314/PA-JPEG-5.jpeg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Enterprising investors might also consider adding a small position in SANA. There's asymmetric upside potential if follow‑up cohorts validate the initial results. My subscribers and I bought shares in the company earlier this year, and then LEAPS on it last week, now that the stock has options traded on it.
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/p/trade-alert-pharma-panic"><img loading="lazy" decoding="async" width="917" height="617" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082502/Trade-Alert.jpg" alt="" class="wp-image-13076" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082502/Trade-Alert.jpg 917w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082502/Trade-Alert-300x202.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082502/Trade-Alert-768x517.jpg 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
Our LEAPS expire in January, 2027.
If you want a heads up when we place our next trade, you can subscribe to the Portfolio Armor trading Substack below.&nbsp;
If you&#8217;d like to stay in touch
You can scan for optimal hedges for individual securities, find our current top ten names, and&nbsp;create hedged portfolios&nbsp;on&nbsp;<a href="https://portfolioarmor.com/">our website</a>.&nbsp;You can also follow Portfolio Armor on X&nbsp;<a href="https://twitter.com/portfolioarmor">here</a>, or become a free subscriber to our trading Substack using the link below (we&#8217;re using that for our occasional emails now).
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/"><img loading="lazy" decoding="async" width="581" height="372" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082648/Widget-5.jpg" alt="" class="wp-image-13077" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082648/Widget-5.jpg 581w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082648/Widget-5-300x192.jpg 300w" sizes="(max-width: 581px) 100vw, 581px" /></a></figure>

Options

Opinion

DXCM

PODD

SANA

The End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giants

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has outperformed the market over the past 5 years by 21.77% on an annualized basis producing an average annual return of 37.04%. Currently, Eli Lilly has a market capitalization of $681.71 billion. 
Buying $100 In LLY: If an investor had bought $100 of LLY stock 5 years ago, it would be worth $479.48 today based on a price of $759.00 for LLY at the time of writing.
<h3>Eli Lilly's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747427413_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$290.00</td>
<td>$37.1K</td>
<td>3.3K</td>
<td>44.8K</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/23/25</td>
<td>$65.00</td>
<td>$28.7K</td>
<td>110</td>
<td>2.2K</td>
</tr>
<tr>
<td>PHAT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$5.00</td>
<td>$138.9K</td>
<td>13.5K</td>
<td>2.0K</td>
</tr>
<tr>
<td>CLOV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$3.50</td>
<td>$40.5K</td>
<td>8.0K</td>
<td>1.5K</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$60.00</td>
<td>$38.2K</td>
<td>3.4K</td>
<td>566</td>
</tr>
<tr>
<td>TMDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$60.00</td>
<td>$617.0K</td>
<td>1.2K</td>
<td>400</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$500.00</td>
<td>$47.0K</td>
<td>648</td>
<td>205</td>
</tr>
<tr>
<td>EXEL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$47.00</td>
<td>$25.7K</td>
<td>0</td>
<td>43</td>
</tr>
<tr>
<td>ELV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$380.00</td>
<td>$28.1K</td>
<td>40</td>
<td>22</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a call option sweep that happens to be bearish, is expiring today. Parties traded 105 contract(s) at a $290.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $37.1K, with a price of $360.0 per contract. There were 3397 open contracts at this strike prior to today, and today 44848 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a put option trade with bullish sentiment. It expires in 7 day(s) on May 23, 2025. Parties traded 42 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $28.7K, with a price of $685.0 per contract. There were 110 open contracts at this strike prior to today, and today 2278 contract(s) were bought and sold. 
• Regarding PHAT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>), we observe a call option trade with bearish sentiment. It expires in 91 day(s) on August 15, 2025. Parties traded 1985 contract(s) at a $5.00 strike. The total cost received by the writing party (or parties) was $138.9K, with a price of $70.0 per contract. There were 13569 open contracts at this strike prior to today, and today 2020 contract(s) were bought and sold. 
• Regarding CLOV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>), we observe a call option sweep with bullish sentiment. It expires in 245 day(s) on January 16, 2026. Parties traded 500 contract(s) at a $3.50 strike. This particular call needed to be split into 20 different trades to become filled. The total cost received by the writing party (or parties) was $40.5K, with a price of $81.0 per contract. There were 8018 open contracts at this strike prior to today, and today 1529 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a call option trade that happens to be bearish, expiring in 35 day(s) on June 20, 2025. This event was a transfer of 100 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $38.2K, with a price of $382.0 per contract. There were 3468 open contracts at this strike prior to today, and today 566 contract(s) were bought and sold. 
• Regarding TMDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>), we observe a call option trade with bearish sentiment. It expires in 63 day(s) on July 18, 2025. Parties traded 100 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $617.0K, with a price of $6170.0 per contract. There were 1255 open contracts at this strike prior to today, and today 400 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a put option sweep with bearish sentiment. It expires in 245 day(s) on January 16, 2026. Parties traded 43 contract(s) at a $500.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $47.0K, with a price of $1095.0 per contract. There were 648 open contracts at this strike prior to today, and today 205 contract(s) were bought and sold. 
• Regarding EXEL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>), we observe a put option sweep with bearish sentiment. It expires in 189 day(s) on November 21, 2025. Parties traded 43 contract(s) at a $47.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $25.7K, with a price of $614.0 per contract. There were 0 open contracts at this strike prior to today, and today 43 contract(s) were bought and sold. 
• Regarding ELV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), we observe a put option sweep with bullish sentiment. It expires in 63 day(s) on July 18, 2025. Parties traded 19 contract(s) at a $380.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $28.1K, with a price of $1480.0 per contract. There were 40 open contracts at this strike prior to today, and today 22 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLOV

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

EXEL

Hims & Hers Health, Inc. Class A Common Stock

HIMS

PHAT

TMDX

9 Health Care Stocks With Whale Alerts In Today's Session

<a href="https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease#:~:text=The%20Lumipulse%20G%20pTau217%2F%C3%9F,and%20symptoms%20of%20the%20disease">https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease#:~:text=The%20Lumipulse%20G%20pTau217%2F%C3%9F,and%20symptoms%20of%20the%20disease</a>.

General

ACIU

ANVS

BIIB

DNLI

PRTA

RHHBF

RHHBY

SAVA

'FDA Clears First Blood Test Used In Diagnosing Alzheimer's Disease; New Test Provides Less Invasive Option, Reduces Reliance On Pet Scans And Increases Diagnosis Accessibility' - FDA

On May 12, President Donald Trump followed through on a campaign promise by signing an Executive Order (EO) mandating that pharmaceutical companies lower their prescription drug prices in the US to those seen abroad.
At a media event, Trump told reporters he was aiming for price cuts of between 59% and 90% and gave drug companies 30 days to play ball.
Wall Street digested the news, and while major biopharma stocks saw share prices drop the day the EO was announced, most industry stocks rebounded.&nbsp;
Here are three pharma stocks that won&#8217;t just rebound, but are poised to soar because of Trump&#8217;s executive order.
<h1 class="wp-block-heading">Team Trump on Solid Ground?</h1>
Nobody&#8217;s denying that US drug prices are out of whack. A 2024 RAND Corporation study concluded US drug prices were approximately three times higher than those in 33 other developed countries.
Presidents have full power to order such a price cut from a private industry, at least in part.
&#8220;That&#8217;s especially the case in sectors like healthcare where government programs like Medicare are massive buyers,&#8221; said Lou Carter, founder and CEO at the Best Practice Institute in Palm Beach Gardens, Fla. &#8220;Policy isn&#8217;t just about law—it&#8217;s about leverage. This EO uses the weight of public programs to force pricing accountability, and that&#8217;s smart business when you&#8217;re managing taxpayer funds.&#8221;
Congress and the courts can try to stop the EO in its tracks, but success on that front is unlikely.&nbsp;
&#8220;Politically, it&#8217;s tough to argue against lower drug prices,&#8221; Carter said. &#8220;Even if pharma lobbies hard, most lawmakers know it&#8217;s political suicide to oppose something that helps seniors afford insulin. If this goes to court, it&#8217;ll hinge on procedural questions—not on whether the move is popular or right.&#8221;
<h1 class="wp-block-heading">Bigger Drug Makers are Hardest Hit</h1>
Given the size and scope of the EO, it&#8217;s no surprise that the more substantial drug companies may find themselves in financial trouble.&nbsp;
&#8220;Large-cap biotech and specialty pharma companies with heavy Medicare exposure like Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) or Regeneron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) could be hit hardest,&#8221; said Dr. Will Soliman, Founder and CEO of the New York City-based Accreditation Council for Medical Affairs. &#8220;They rely on high-margin (Medicare) Part B drugs.&#8221;
Vertical-oriented drug makers could also feel the heat from the EO.&nbsp;
&#8220;Specialized oncology manufacturers like Bristol Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) have greater exposure than diversified pharmaceutical companies with broader portfolio ranges,&#8221; said Seann Malloy, founder and managing partner of Malloy Law Offices in Bethesda, Md. &#8220;Small to mid-cap biotechnology companies with early commercial products often fall outside immediate impact zones due to limited Medicare utilization and existing price protection provisions. &#8220;
&#8220;The executive order&#8217;s key element mandates that Medicare&#8217;s prescription drug payments align with the lowest prices in other developed countries, essentially using international reference pricing,&#8221; Malloy said. &#8220;While some demonstration projects will start within 30 days, full implementation across all provisions will take longer, likely 6-12 months, due to necessary regulatory development. &#8220;
Timing could play a big role in determining how much of an impact the EO will have on biotech drug stocks, if any.
Initially, the order focuses on physician-administered drugs under Medicare Part B but may later include retail prescriptions under Part D. &#8220;This staged implementation means the immediate and long-term market effects will differ, a point often missed by investors,&#8221; Malloy noted. &#8220;Despite initial impressions of swift price changes, significant revenue impacts will likely be delayed by extensive regulatory procedures.&#8221;
Additionally, overseas drug providers may face stiff headwinds from the Trump drug price directive.
&#8220;International manufacturers are most vulnerable,&#8221; said Javier Palomarez, founder and CEO of the United States Hispanic Business Council. &#8220;Many of them ship to the United States because of the return on investment &#8211; eroding that return dampens the incentive and ability to ship medicines across the world, which could lead to total loss of US market access for some companies.&#8221;
<h1 class="wp-block-heading">Three Drug Stocks That Bear Watching Over the Next 30 Days</h1>
Biotech investors looking to leverage the Trump EO should understand Trump&#8217;s intention to &#8220;cut out the middleman,&#8221; as he said in his May 12 press event. This translates to good news for actual drug manufacturers and not-so-good news for so-called pharmacy-benefit managers.
PBM&#8217;s act as intermediaries between health insurance companies, big employers, drug manufacturers, insurers, and patients. While they don&#8217;t produce prescription drugs, they handle the more mundane side of the drug business, like claims processing and negotiating prescription drug prices.
The big drug producers have historically blamed the PBMs for sky-high drug prices and would likely back any initiative that expands the direct-to-consumer drug marketplace. In that scenario, no insurers are needed, as drug consumers could deal directly with drug manufacturers to buy the medicines they need, presumably at a more affordable price.
Investors in that marketplace would want large drug makers, and big PBMs would not. These three drug stocks stand out on the plus side.
<h2 class="wp-block-heading">Eli Lilly</h2>
Drug manufacturing giant Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is priced high at $730 per share, but it&#8217;s a stock that would likely prosper in a direct-to-consumer prescription drug marketplace. The stock is off by 5.0% year-to-date, but 26 Wall Street analysts who track LLY give it a top rating. The company&#8217;s recent earnings per share are off the charts, with an upward spike of 106% in EPS in 2024 and an estimated 68% in 2025. The stock is off 20% compared to recent highs, which could mean a nice discount for a drug industry stalwart.
<h2 class="wp-block-heading">Novo Nordisk</h2>
Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has experienced market woes that preceded the Trump E/O, as competitors continue to chew into market share in the lucrative weight loss drug market. Particularly damaging was a recent study that concluded patients taking Eli Lilly&#8217;s Zepbound were losing weight faster than with Novo&#8217;s Wegovy. That&#8217;s one big reason Novo Nordisk has seen its share price fall by 50% over the past year. Yet the stock is in rebound mode right now, up 13.9% over the past month. A $2.2 billion deal between Novo and Septerna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEPN#NASDAQ">SEPN</a>) to develop weight loss pills is seen as a big step by analysts and big names like Goldman Sachs and JP Morgan are sticking to their buy calls on the stock. Meanwhile, a larger group of industry analysts is out with a consensus 50% share price upside from current levels.
<h2 class="wp-block-heading">AbbVie</h2>
AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) is a genuine cash flow producer that seems immune to any political interference from Washington, D.C. The drug manufacturer has a diverse set of popular prescription drugs, like Botox, Humira, Rinvoq, and Skyrizi. The stock only fell by a paltry 1% on the E news this week, and is up 5% over the past month. It also comes with a healthy 3.6% dividend for income-minded investors, a robust drug pipeline in play, and a brand new regulatory &#8220;green light&#8221; for its lung cancer drug Emrelis, supporting the rationale that ABBV shares should continue to climb in 2025.
<a href="https://benzinga.zoom.us/webinar/register/WN_OJ2FBspHSJSSVNlW8zGapw/?utm_campaign=webinar052025&amp;utm_adType=sponsorad&amp;utm_ad=RD051925/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_medium=newsletter">Smart Options Plays for Traders Watching Junk Bonds</a> Credit markets are breaking down. Volatility is back. Join Ryan Faloona, Anne-Marie Baiynd, and Tim Melvin live on May 20 at 6 PM ET to see how seasoned traders are using junk bond signals and short-term options to hedge, profit, and stay a step ahead. <a href="https://benzinga.zoom.us/webinar/register/WN_OJ2FBspHSJSSVNlW8zGapw/?utm_campaign=webinar052025&amp;utm_adType=sponsorad&amp;utm_ad=RD051925/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_medium=newsletter">Save your seat for this live tactical session.</a>
Image via Shutterstock

ABBV

AMGN

REGN

SEPN

3 Stocks That Will Profit From Trump's Drug Price Cut

Wall Street fought for a fifth consecutive day of gains on Friday, with major indexes edging slightly higher by midday in New York as investors continued to digest the week's significant trade breakthroughs and <a href="https://www.benzinga.com/news/econ-s">recalibrate their economic expectations.</a>
The S&amp;P 500 rose 0.1% to 5,925, its highest level since early March, while the Nasdaq 100 held firm after a strong prior session. Gains were broad but cautious as markets balanced optimism over de-escalating tariffs with growing macro concerns. 
Healthcare stocks rebounded from recent underperformance, buoyed by a rally in Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), while the energy sector lagged as crude prices cooled.
The U.S. dollar surged after the <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45470155/consumer-sentiment-crashes-to-5-year-lows-as-inflation-fears-reach-1981-levels">University of Michigan's consumer sentiment report</a> delivered one of the bleakest stagflationary signals in recent decades. 
The headline Consumer Sentiment Index dropped to its lowest level since June 2020, while the Consumer Expectations subindex hit levels not seen since 1980. Year-ahead inflation expectations soared to 7.3%, the highest since late 1981. 
The spike in inflation fears rattled rate-cut bets. Fed funds futures slashed the odds of a June interest rate cut to just 5%, effectively pricing out any move next month. 
Markets now fully price the first rate cut only by October 2025, with a second possibly arriving in December.
Treasury yields rose as bond prices fell, with the 30-year yield rising back to 4.90%, following the dismal sentiment data. The combination of rising yields and a stronger dollar weighed heavily on gold, which dropped 1.8% and is headed for its worst weekly performance since November 2024. 
In crypto, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) bounced back and reclaimed the $104,500 level. 
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,103.26</td>
<td>0.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,932.74</td>
<td>0.3%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,424.05</td>
<td>0.2%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,350.21</td>
<td>0.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:15 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.2% up to $591.88.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.2% to $424.32.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;edged 0.1% up $520.03.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.4% to $209.16.</li>
<li>The&nbsp;Health Care&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) outperformed, up 1%; the&nbsp;Energy Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 0.5%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
<ul class="wp-block-list">
<li>Applied Materials inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) fell 6.1% following a miss in revenue forecasts and revised guidance amid trade challenges with China. </li>
<li>Take-Two Interactive Software inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) fell 2% after missing earnings expectations last quarter. </li>
</ul>
Read now: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/large-cap/25/05/45472025/loebs-third-point-exits-meta-tesla-rotates-into-staples-telecom-industrials">Loeb&#8217;s Third Point Exits Meta, Tesla, Rotates Into Staples, Telecom, Industrials </a></li>
</ul>
Photo: Shutterstock

Large Cap

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Economics

ETFs

$BTC

AMAT

SPDR Dow Jones Industrial Average ETF Trust

GLOB

TTWO

Select Sector SPDR-Consumer Discretionary

Stocks Fight For Fifth Day Of Gains, Dollar Rebounds As Inflation Fears Go Haywire: What's Driving Markets Friday?

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) on Thursday entered into a strategic global research collaboration and licensing agreement with Rznomics Inc., a&nbsp;South Korea-based biopharmaceutical company specializing <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">in RNA-based therapeutics</a>.
The agreement focuses on developing and commercializing RNA-editing therapies using Rznomics&#8217; proprietary trans-splicing ribozyme platform.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45176293/eli-lilly-stock-offers-buying-opportunity-for-goldman-sachs-concerns-over-cvs-setback-are-overblown-analysts-say" rel="noreferrer noopener">Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say</a>
The collaboration <a target="_blank" href="https://www.prnewswire.com/news-releases/rznomics-enters-global-licensing-agreement-with-eli-lilly-for-rna-editing-therapeutics-302456852.html" rel="noreferrer noopener">focuses</a> on discovering and developing RNA-editing therapeutics for sensorineural hearing loss. Rznomics will conduct early-stage research according to the jointly approved research plans, while Lilly will assume responsibility for further development and commercialization.
If Lilly exercises all available options under the agreement, the total deal value could reach more than&nbsp;$1.3 billion and separate royalties on product sales. The upfront payment was not disclosed.&nbsp;
&#8220;We are thrilled to collaborate with Lilly, a global leader in pharmaceutical innovation,&#8221; said Dr. Seong-Wook Lee, CEO of Rznomics. &#8220;This partnership validates our trans-splicing ribozyme platform and opens the door to treating previously intractable diseases with precision RNA therapeutics.&#8221;
The partnership marks a significant milestone for Rznomics as it seeks to expand its presence in the global biotech arena. For Lilly, the deal aligns with its broader strategy to build a leading RNA therapeutics pipeline.
Price Action: LLY stock is up 2.61% at $734.24 at the last check on Thursday.
<h2 class="wp-block-heading">Eli Lilly Stock Prediction For 2025</h2>
Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on a company&#8217;s fundamentals and expected future earnings to arrive at a price target and recommendation for the stock.
Shares of Eli Lilly have an average 1-year price target of $966.43, representing an expected upside of 31.6%.
Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. One analyst has bearish recommendations on Eli Lilly, while six analysts have bullish ratings. Morgan Stanley&#8217;s street high price target is $1124.0, while HSBC&#8217;s street low is $700.0.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45441833/deere-shares-rise-after-q2-beat-despite-steep-sales-declines-across-segments" target="_blank" rel="noreferrer noopener">Deere Shares Rise After Q2 Beat Despite Steep Sales Declines Across Segments</a></li>
</ul>
Image: Shutterstock

Contracts

Eli Lilly Collaborates With Rznomics On Hearing Loss Treatment In $1.3 Billion Pact

<ul>
<li>Co-development of precision RNA therapeutics for inherited hearing loss treatment</li>
</ul>
SEONGNAM, South Korea, May 15, 2025 /PRNewswire/ -- Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today that it has entered into a strategic global research collaboration and licensing agreement with Eli Lilly and Company&nbsp;to develop and commercialize novel RNA-editing therapies using Rznomics' proprietary trans-splicing ribozyme platform.
The collaboration focuses on the discovery and development of RNA-editing therapeutics for sensorineural hearing loss. Rznomics will conduct early-stage research according to the jointly approved research plans, while Lilly will assume responsibility for further development and commercialization.
If Lilly exercises all available options under the agreement, the total deal value could reach more than $1.3 billion, as well as separate royalties on product sales. In line with the mutual understanding between the two companies, the upfront payment was not disclosed.&nbsp;

Rznomics Enters Global Licensing Agreement With Eli Lilly For RNA-editing Therapeutics; If Lilly Exercises All Available Options Under The Agreement, The Total Deal Value Could Reach More Than $1.3B, As Well As Separate Royalties On Product Sales; The Upfront Payment Was Not Disclosed

Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced on Wednesday that it will invest at least $20 billion in the <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">U.S. through 2030</a>.
Research and development, plus U.S. manufacturing, will receive the bulk of the spending.
The company also expects higher job creation within the communities where Sanofi and its partners are located, which will help <a href="https://www.benzinga.com/pressreleases/25/05/n45414947/sanofi-to-invest-at-least-20-billion-in-the-us-through-2030-growing-investments-in-science-and-exp" target="_blank" rel="noreferrer noopener">enhance the U.S. supply chain</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44981281/french-drugmaker-sanofi-clocks-20-q1-profit-growth-forecasts-strong-rebound-in-annual-profit" rel="noreferrer noopener">French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit</a>
Sanofi has 13,000 US-based employees, according to CEO Paul Hudson.
&#8220;Our expected investments in the US will be substantial and will help ensure the production of key medicines in the U.S.,&#8221; he added.
Sanofi also expects to partner with other domestic manufacturers to help ensure the production of medicines in the U.S.  
Earlier in May, U.S. President&nbsp;Donald Trump's&nbsp;signed an executive order to promote prescription drug manufacturing in the U.S., streamlining the path for companies to build new production sites as potential tariffs on&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">imported medicines loom</a>.
The White House wants facilities to come on board at a faster rate. It <a href="https://www.whitehouse.gov/presidential-actions/2025/05/regulatory-relief-to-promote-domestic-production-of-critical-medicines/?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" target="_blank" rel="noreferrer noopener">estimates</a> that it can currently take five to 10 years to build new pharmaceutical manufacturing capacity, which it calls "unacceptable from a national-security standpoint.&#8221;
It&#8217;s not just Sanofi. <a href="https://www.benzinga.com/25/05/45234032/fda-expands-surprise-inspections-at-foreign-drug-and-food-facilities-targets-double-standards-in-overseas-manufacturing-oversight" target="_blank" rel="noreferrer noopener">Amid tariff uncertainty</a>, many drug companies are investing to boost production within the U.S.:
<ul class="wp-block-list">
<li>Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) doubled&nbsp;<a href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target" target="_blank" rel="noreferrer noopener">domestic medicine production</a>.</li>
<li>Thermo Fisher Scientific Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) announced it would invest an additional $2 billion in the U.S. over&nbsp;<a href="https://www.benzinga.com/general/health-care/25/04/44995428/thermo-fisher-doubles-down-on-us-manufacturing-in-2b-expansion-plan" target="_blank" rel="noreferrer noopener">the next four years</a>.</li>
<li>Medtech firm&nbsp;Becton, Dickinson, and Company&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) also announced its intention to invest&nbsp;$2.5 billion&nbsp;in U.S. manufacturing capacity&nbsp;<a href="https://www.benzinga.com/general/health-care/25/05/45140102/potential-tariff-bites-into-becton-dickinson-2025-profit-outlook-company-will-invest-2-5-billion-to-boost-us-manufacturing" target="_blank" rel="noreferrer noopener">over the next 5 years</a>.</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)  seeks to nearly double its manufacturing capacity through a new agreement with <a href="https://www.benzinga.com/general/biotech/25/04/44931246/regeneron-partners-with-japan-based-fujifilm-to-bolster-us-manufacturing-capacity-via-3-billion-deal" target="_blank" rel="noreferrer noopener">FUJIFILM Diosynth Biotechnologies</a>.</li>
<li>Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) unveiled a $23 billion investment plan to expand in the U.S. <a href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertaint" target="_blank" rel="noreferrer noopener">over the next five years</a>.</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) plans to invest more than <a href="https://www.benzinga.com/markets/equities/25/03/44433978/johnson-johnson-to-invest-55-billion-in-us-to-boost-manufacturing-drug-discovery" target="_blank" rel="noreferrer noopener">$55 billion in the U.S. over the next four years</a>.</li>
<li>Roche Holdings AG&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>)&nbsp;announced that it will invest $50 billion in the U.S. over&nbsp;<a href="https://www.benzinga.com/topic/pharmaceuticals" target="_blank" rel="noreferrer noopener">the next five years.</a></li>
<li>Bristol-Myers Squibb &amp; Co.'s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)&nbsp;Christopher Boerner, chair and chief executive officer,&nbsp;<a href="https://www.statnews.com/2025/05/05/bristol-myers-squibb-pharmaceutical-policy-us-trump-administration-innovation-tariffs/?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" target="_blank" rel="noreferrer noopener">shared</a>&nbsp;plans to invest $40 billion in U.S. R&amp;D, technology, and manufacturing over the next five years in an op-ed published by Statnews.</li>
</ul>
Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) is one pharma company that did not highlight investments in new manufacturing plants. The company noted that they already have significant capacity and flexibility to manufacture <a href="https://www.benzinga.com/general/biotech/25/04/45118145/pfizer-ceo-albert-bourla-emphasizes-national-security-in-us-drug-manufacturing" target="_blank" rel="noreferrer noopener">products in the U.S</a>.
Price Action: Sanofi stock is down 1.53% at $49.20 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45407486/novo-nordisk-inks-22-billion-deal-with-septerna-to-develop-oral-weight-loss-and-diabetes-drugs" target="_blank" rel="noreferrer noopener">Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs</a></li>
</ul>
Image: Shutterstock

Movers

Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030

WIIM

GILD

Shares of pharmaceutical stocks are trading lower. The sector may down on continued weakness amid President Trump's drug pricing executive order.

Deep-pocketed investors have adopted a bearish approach towards Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LLY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 69 extraordinary options activities for Eli Lilly. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 34% leaning bullish and 40% bearish. Among these notable options, 25 are puts, totaling $2,733,522, and 44 are calls, amounting to $3,125,976.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $300.0 and $1200.0 for Eli Lilly, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Eli Lilly's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly's whale trades within a strike price range from $300.0 to $1200.0 in the last 30 days. 
<h3>Eli Lilly Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747238567_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$12.35</td>
<td>$11.8</td>
<td>$12.35</td>
<td>$800.00</td>
<td>$617.5K</td>
<td>3.2K</td>
<td>604</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/18/26</td>
<td>$381.7</td>
<td>$376.15</td>
<td>$378.92</td>
<td>$1100.00</td>
<td>$493.2K</td>
<td>0</td>
<td>186</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/18/26</td>
<td>$381.6</td>
<td>$376.25</td>
<td>$378.92</td>
<td>$1100.00</td>
<td>$379.0K</td>
<td>0</td>
<td>186</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/23/25</td>
<td>$3.45</td>
<td>$3.4</td>
<td>$3.4</td>
<td>$670.00</td>
<td>$262.5K</td>
<td>152</td>
<td>1.0K</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$357.0</td>
<td>$351.0</td>
<td>$354.0</td>
<td>$1080.00</td>
<td>$212.4K</td>
<td>5</td>
<td>6</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Following our analysis of the options activities associated with Eli Lilly, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Eli Lilly</h3>
<ul>
<li>With a trading volume of 2,442,567, the price of LLY is down by -2.66%, reaching $726.23.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 85 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Eli Lilly</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $908.33.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from HSBC lowers its rating to Reduce with a new price target of $700. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Buy rating on Eli Lilly with a target price of $1050. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $975. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Eli Lilly, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Unpacking the Latest Options Trading Trends in Eli Lilly

Shares of pharmaceutical stocks are trading lower amid President Trump's drug pricing executive order.

ISRG

Live On CNBC, Stephanie Link Announces Sold Eli Lilly and Co; Announces Bought More Intuitive Surgical

The United States and China agreed to slash their retaliatory tariffs by over 100 percentage points, pausing a spiraling trade war that had threatened<a href="https://www.benzinga.com/news/econ-s"> to choke global growth.</a>
<h3 class="wp-block-heading">What's In The Deal?</h3>
The agreement establishes a 90-day reset, slashing U.S. tariffs on Chinese goods from 145% to 30%, and Chinese tariffs on U.S. goods from 125% to 10%, starting May 14. 
The decision stems from high-level negotiations in Geneva, led by U.S. Treasury Secretary Scott Bessent and China's Vice Premier He Lifeng.
The truce halts one of the steepest protectionist escalations in recent history, following President Donald Trump's aggressive "Liberation Day" trade tariffs launched on April 2.
"We reached an agreement on a 90-day pause and substantially moved down the tariff levels," Bessent said in a press conference. 
"Both countries represented their national interests very well, but we concluded we have shared interest in balanced trade."
<h3 class="wp-block-heading">Tariff Truce Cools Recession And Inflation Risks</h3>
The tariff rollback offers more than diplomatic relief — it also addresses growing fears of a U.S. economic slowdown and resurgent inflation. By averting the triple-digit import taxes that threatened to choke global trade, the deal removes a significant source of economic uncertainty that had weighed on business investment and consumer confidence.
Recession probabilities have sharply declined in response. 
The latest market-based forecast from Kalshi shows a 46% chance of a U.S. recession this year, down from 60% at the end of April, reflecting improving sentiment. Notably, consumer spending and corporate earnings had begun showing early signs of strain under the tariff shock imposed in April.
On the inflation front, the agreement is expected to ease price pressures on goods most impacted by the trade war — including electronics, automotive parts and industrial equipment.
Ahead of Tuesday's official April Consumer Price Index report, economists expect a return to monthly inflation growth: headline prices are forecast to rise 0.3%, reversing March's 0.1% dip. Core inflation is also expected to rise 0.3%, while annual inflation rates are seen holding steady at 2.4% for headline and 2.8% for core.
<h3 class="wp-block-heading">Why Markets Cheered</h3>
U.S. equity futures soared as the news hit, with futures on the S&amp;P 500 climbing 3.13% to 5,836.66, those on the Nasdaq 100 jumping 4.05%, and Dow futures up 2.62%. 
The U.S. dollar index – as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – surged 1.4%, with the greenback rallying 2% against the Japanese yen. 
Meanwhile, 2-year Treasury yields rose 10 basis points to 4%, as traders dialed back expectations for a near-term Federal Reserve rate cut. The odds of a June cut fell to 11%, down from 25% a week ago, per CME FedWatch.
Gold – as tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) – dropped 2.9%, with investors rotating out of safe havens, and oil climbed 3.9% to $63.40 amid improving global demand prospects.
<h3 class="wp-block-heading">Who Wins On Wall Street?</h3>
U.S. equities rallied sharply as investors welcomed the truce between Washington and Beijing. 
Trade-sensitive and consumer-facing stocks led the premarket advance, reflecting relief over lower input costs and reduced supply chain disruption. Technology and industrials also posted notable gains.
Top Gainers – S&amp;P 500
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Company</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stanley Black &amp; Decker Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>)</td>
<td>+12.07%</td>
</tr>
<tr>
<td>Best Buy Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>)</td>
<td>+10.42%</td>
</tr>
<tr>
<td>Microchip Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>)</td>
<td>+9.29%</td>
</tr>
<tr>
<td>GE HealthCare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>)</td>
<td>+8.94%</td>
</tr>
<tr>
<td>NRG Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>)</td>
<td>+8.08%</td>
</tr>
</tbody>
</table>
</figure>
Top Premarket Gainers – Nasdaq 100
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Company</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microchip Technology Inc.</td>
<td>+9.29%</td>
</tr>
<tr>
<td>GE HealthCare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>)</td>
<td>+8.94%</td>
</tr>
<tr>
<td>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>+8.44%</td>
</tr>
<tr>
<td>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</td>
<td>+8.07%</td>
</tr>
<tr>
<td>ON Semiconductor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>)</td>
<td>+8.02%</td>
</tr>
</tbody>
</table>
</figure>
Top Premarket Losers – S&amp;P 500
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Company</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newmont Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>)</td>
<td>-5.24%</td>
</tr>
<tr>
<td>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</td>
<td>-3.60%</td>
</tr>
<tr>
<td>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</td>
<td>-3.58%</td>
</tr>
<tr>
<td>Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</td>
<td>-3.38%</td>
</tr>
<tr>
<td>Westinghouse Air Brake Technologies Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>)</td>
<td>-3.17%</td>
</tr>
</tbody>
</table>
</figure>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/05/45341884/apple-amazon-nvidia-rise-in-monday-premarket-as-us-china-agree-to-90-day-tariff-truce-neither-side-wants-a-decoupling">Apple, Amazon, Nvidia Rise In Monday Premarket As US, China Agree To 90-Day Tariff Truce: &#8216;Neither Side Wants A Decoupling&#8217;</a><span class="author" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ;"></li>
</ul>
Photo: emin kuliyev/Shutterstock

Government

Regulations

Bonds

Forex

AMZN

GEHC

MCHP

TSLA

PowerShares DB US Dollar Index Bullish Fund

Wall Street Rips Higher As Tariff Truce Halts US–China Economic Escalation

<a href="https://www.cnbc.com/2025/05/12/trump-drug-pricing-order-most-favored-nation.html">https://www.cnbc.com/2025/05/12/trump-drug-pricing-order-most-favored-nation.html</a>
&nbsp;
<ul>
<li>President Donald Trump will revive a controversial policy that aims to slash drug costs by tying the amount the government pays for some medicines to lower prices abroad, White House officials said.</li>
<li>The order is a blow to the pharmaceutical industry, which is already bracing for Trump&#39;s planned tariffs on prescription drugs.</li>
<li>It is Trump&#39;s latest effort to try to rein in U.S. prescription drug prices, which are two to three times higher on average than those in other developed nations.</li>
</ul>
&nbsp;

MRNA

'Trump To Sign Order To Cut Some U.S. Drug Prices To Match Those Abroad' - CNBC

Mark Cuban, the billionaire entrepreneur, challenged Trump-supporter and political activist Charlie Kirk&#8216;s stance on high drug prices, asserting that Pharmacy Benefit Managers (PBMs) are the main culprits, not Big Pharma.
What Happened:&nbsp;Cuban criticized Kirk&#8217;s&nbsp;focus on Big Pharma as&nbsp;the primary driver of high drug prices. Instead, Cuban pointed to PBMs as the major offenders&nbsp;due to their opaque pricing&nbsp;practices and market dominance. Cuban highlighted the lack of transparency in PBMs&#8217; contracts, which often prohibit disclosing pricing details. He challenged&nbsp;Kirk to obtain a net&nbsp;price list from his company&#8217;s PBM. 
Meanwhile, Charlie Kirk, the founder of Turning Point USA, has regularly raised questions on the practices of Big Pharma through his posts and podcasts.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Charlie , you aren&#39;t close. Drug prices are too damn high. But the big culprit isn&#39;t the brand manufacturers, it&#39;s the big middlemen. Namely PBMs. They work so hard to distort pricing the first lines in their contracts with everyone is &quot;you can&#39;t disclose any of this &quot; How bad… <a href="https://t.co/oMnlvlOPtl">https://t.co/oMnlvlOPtl</a>
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1921755430708969767?ref_src=twsrc%5Etfw">May 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Cuban&#8217;s post aligns&nbsp;with a 2022 FTC investigation&nbsp;into PBMs&#8217;&nbsp;role in rising drug costs&nbsp;through practices like spread pricing. Moreover, according to a 2023 Bipartisan&nbsp;Policy Center, six PBMs control&nbsp;95% of the private market. 
He supports Trump's Executive Order to lower drug prices by 30-80%, suggesting that targeting PBMs, such as separating formularies and mandating claim disclosures, could make brand medications cheaper than in many countries, building on his own efforts with Cost Plus Drugs to cut out middlemen and reduce costs.
In one of his initial responses, Mark Cuban expressed support for the move, stating it could &#8220;force transparency,&#8221; even if the President can&#8217;t mandate price reductions.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/25/05/45338281/trump-has-a-proven-track-record-of-being-an-absolute-failure-says-gov-tim-walz-we-dont-need-to-run-governmen" target="_blank" rel="noreferrer noopener">Trump Has A &#8216;Proven Track Record Of Being An Absolute Failure,&#8217; Says Gov. Tim Walz—&#8217;We Don&#8217;t Need To Run Government Like A Business&#8217;</a>
Why It Matters: Cuban&#8217;s comments come in the wake of President Donald Trump&#8216;s announcement of a sweeping executive order aimed at slashing prescription drug prices. The order, which Trump referred to as the &#8220;most consequential executive order&#8221; in U.S. history, is set to implement a &#8220;Most Favored Nations&#8221; <a href="https://www.benzinga.com/general/health-care/25/05/45341590/trumps-drug-pricing-executive-order-could-rattle-pharma-stocksprice-cuts-up-to-80">policy requiring</a> pharmaceutical companies to charge U.S. consumers no more than the lowest price they offer for the same drug in any other country.
Cuban, despite being a Trump critic, has <a href="https://benzinga.com/markets/25/04/44866755/mark-cuban-says-this-trump-healthcare-order-could-save-hundreds-of-billions">expressed support</a> for Trump&#8217;s healthcare order, emphasizing its potential to reform the role of PBMs in the U.S. healthcare system and save billions. He believes&nbsp;that targeting PBMs—such as separating&nbsp;formularies and mandating claim disclosures—could&nbsp;make brand medications cheaper than&nbsp;in many countries.
Meanwhile, Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) were trading 2% to 5% lower in Monday&#8217;s premarket in response to Trump&#8217;s executive order.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/05/45328061/bitcoin-ethereum-xrp-dogecoin-enter-weekend-strong-long-dips-140000-is-programmed-trader-says" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, XRP, Dogecoin Enter Weekend Strong: &#8216;Long Dips, $140,000 Is Programmed,&#8217; Trader Says &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Mark Cuban Slams Charlie Kirk Over Drug Price Debate, Says PBMs — Not Big Pharma — Are The Real Villains: 'For Your Company…Ask Your PBM For A List Of Claims'

Eli Lilly and Company&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound demonstrated superior weight reduction compared to Novo Nordisk A/S&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegovy in a 72-week head-to-head trial.
What Happened: Participants treated with tirzepatide (Zepbound) achieved an average weight loss of 20.2%, compared to 13.7% with semaglutide (Wegovy), representing a 47% greater relative weight reduction, according to detailed results from a direct comparison trial published in The New England Journal of Medicine. 
On average, those taking Zepbound lost 50.3 pounds, while those on Wegovy lost 33.1 pounds over the course of the study.
The SURMOUNT-5 Phase 3b open-label clinical trial met its primary endpoint and all five key secondary endpoints, with Zepbound showing superiority across all weight reduction targets. Nearly 65% of Zepbound users achieved at least 15% weight loss compared to 40% on Wegovy, and participants experienced greater waist circumference reduction —7.2 inches versus 5.1 inches.
The safety profile aligned with previous trials, with primarily gastrointestinal-related adverse events that were generally mild to moderate in severity. Discontinuation rates due to adverse events were 6.1% for Zepbound versus 8% for Wegovy.
See Also: <a href="https://www.benzinga.com/25/05/45340117/peter-lynch-said-the-suckers-going-up-is-no-buy-strategy-suggests-two-things-to-look-for-in-a-company-that-suggest-something-different">Peter Lynch Once Lamented People Are &#8216;Careful&#8217; When They Buy A Fridge But Will &#8216;Drop Thousands&#8217; On A Stock Tip They Heard On A Bus</a>
Why It Matters: Zepbound&#8217;s performance in this direct comparison strengthens Lilly&#8217;s position in the rapidly growing weight loss medication market. The drug operates as a dual GIP and GLP-1 receptor agonist, compared to Wegovy, which works solely as a GLP-1 receptor agonist.
The U.S. Food and Drug Administration recently expanded Zepbound&#8217;s approval to include <a href="https://www.benzinga.com/news/25/01/42933134/fda-approves-weight-loss-drug-zepbound-for-sleep-apnea-will-insurance-cover-this-1000-per-month-medication">treatment for moderate-to-severe obstructive sleep apnea</a> in adults with obesity. Clinical trials showed patients experienced an average of 25 fewer breathing interruptions per hour, with up to 50% no longer exhibiting OSA symptoms after one year.
WW International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) recently announced a <a href="https://www.benzinga.com/news/25/04/45073094/weightwatchers-integrates-with-eli-lilly-to-expand-access-to-zepbound-stock-skyrockets-110">partnership with LillyDirect</a> pharmacy provider Gifthealth to simplify access to Zepbound for eligible self-pay clinic members. According to WeightWatchers, 33% of its clinic patients currently use Zepbound as part of their weight management plan, with prescriptions more than doubling in recent months.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45339966/bitcoin-creator-satoshi-nakamotos-estimated-wealth-crosses-bill-gates-amid-apex-cryptos-sharp-rebound">Bill Gates Left Behind By Satoshi Nakamoto: Bitcoin Creator&#8217;s Wealth Now Eclipses That Of Microsoft Co-Founder Amid Crypto&#8217;s Sharp Rebound</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial

<ul>
<li>Participants achieved an average weight loss of 20.2% with Zepbound vs. 13.7% with Wegovy</li>
<li>In key secondary endpoints,&nbsp;Zepbound was superior to Wegovy across all weight reduction targets and waist circumference reduction</li>
</ul>

Reported Earlier, Zepbound (Tirzepatide) Outperforms Wegovy In Head-To-Head Study, Delivering Over 20% Average Weight Loss Over 72 Weeks

On Sunday, President Donald Trump vowed to <a href="https://www.benzinga.com/markets/25/04/44945973/trump-administration-considers-lowering-us-drug-prices-to-international-levels-report">slash prescription drug prices</a> through a sweeping executive order.
What Happened: Trump took to Truth Social and announced plans to sign a new executive order. Under what he called a "most favored nation" pricing policy, the President said the executive order will ensure that "the United States will pay the same price as the Nation that pays the lowest price anywhere in the World."
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="612" height="966" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/11221440/Screenshot-2025-05-12-at-11.14.22.png" alt="" class="wp-image-911175" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/11221440/Screenshot-2025-05-12-at-11.14.22.png 612w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/11221440/Screenshot-2025-05-12-at-11.14.22-190x300.png 190w" sizes="(max-width: 612px) 100vw, 612px" /></figure>
Screenshot From President Donald Trump&#8217;s Truth Social Account
He added that prescription drug prices would drop "almost immediately, by 30% to 80%," and called the move "one of the most consequential Executive Orders in our Country's history."
In response, a user on X, formerly Twitter, expressed skepticism, saying, "It would be nice if Trump&#8217;s super important post about drug prices was really achievable. I think all Democrats would agree&#8230; But like most things Trump brags about, they are pie-in-the-sky promises that can&#8217;t and won&#8217;t actually materialize."
See Also: &nbsp;<a href="https://benzinga.com/news/25/04/44935195/elizabeth-warren-says-if-trump-illegally-fires-fed-chair-powell-hell-crash-our-markets-cause-more-economic-p" target="_blank" rel="noreferrer noopener">Elizabeth Warren Says, ‘If Trump Illegally Fires Fed Chair Powell, He'll Crash Our Markets, Cause More Economic Pain To American Families'</a>
That's where <a href="https://www.benzinga.com/markets/25/04/44866755/mark-cuban-says-this-trump-healthcare-order-could-save-hundreds-of-billions">billionaire entrepreneur</a> and Cost Plus Drugs founder Mark Cuban stepped in. Cuban acknowledged the ambition of Trump's plan but highlighted a more attainable path forward.
"I don't know if he can force the price, but he can force transparency, and that will help," Cuban wrote.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I dont know if he can force the price , but he can force transparency , and that will help. He did it w hospitals Force transparency of contracts, pricing , rebates , claims and a lot could change Biggest thing he could do is encourage brand pharma to sell to cost plus drugs… <a href="https://t.co/vkz3Q2IFkn">https://t.co/vkz3Q2IFkn</a>
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1921710702743417149?ref_src=twsrc%5Etfw">May 11, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It's Important: Last month, Trump issued a <a href="https://benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction">multi-part executive order</a> targeting drug pricing transparency and Medicare cost reduction.
Earlier this month, he signed <a href="https://www.benzinga.com/news/25/05/45232993/trump-orders-fda-to-fast-track-us-drug-production-as-tariff-threat-looms-on-imported-medicines-cites">another executive order directing</a> the Food and Drug Administration to expedite approvals for domestic pharmaceutical manufacturing facilities.
The Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>) and iShares U.S. Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>) rose 2.61% and 2.81%, respectively, over the past month.
Price Action: In after-hours trading, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) was up 0.20%, while Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) increased by 0.32% and 0.13%, respectively. Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) also saw a modest gain of 0.12%, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Photo Courtesy: PeopleImages.com &#8211; Yuri A On Shutterstock.com
Read Next:
<ul class="wp-block-list">
<li><a href="https://benzinga.com/markets/cryptocurrency/25/04/44930938/dogecoin-jumps-7-shiba-inu-up-4-is-a-major-meme-rally-brewing" target="_blank" rel="noreferrer noopener">Dogecoin Jumps 7%, Shiba Inu Up 4%: Is A Major Meme Rally Brewing?</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

iShares Dow Jones US Pharmaceuticals Index Fund

Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency'

These large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol class="wp-block-list">
<li>argenx SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) shares tumbled 15.40% after the <a href="https://www.benzinga.com//node/45275849" target="_blank" rel="noreferrer noopener">company reported first-quarter results</a>.</li>
<li>Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) shares dipped 15.20% after it reported lower-than-expected first-quarter 2025 earnings, and analysts <a href="https://www.benzinga.com//node/45236530" target="_blank" rel="noreferrer noopener">revised the price forecasts</a>.</li>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) stock fell 14.12%.</li>
<li>MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) shares dived 12.96%.</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) shares fell 12.85%. The U.S. Food and Drug Administration (FDA) announced its intent to expand the use of unannounced inspections at foreign manufacturing facilities that produce foods, essential medicines, and other medical products intended <a href="https://www.benzinga.com//node/45234032" target="_blank" rel="noreferrer noopener">for American consumers and patients</a>.</li>
<li>Rocket Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) shares dived 11.97% after reporting <a href="https://www.benzinga.com//node/45299460" target="_blank" rel="noreferrer noopener">first-quarter results</a>, but issuing a weaker-than-expected Q2 sales outlook.</li>
<li>BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) stock was down 11.60% after the <a href="https://www.benzinga.com//node/45205736" target="_blank" rel="noreferrer noopener">company reported quarterly results</a>. Analysts revised the price <a href="https://www.benzinga.com/quote/bntx/analyst-ratings" target="_blank" rel="noreferrer noopener">forecast on the stock</a>.</li>
<li>Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) stock declined 11.33% after the company reported third-quarter results and <a href="https://www.benzinga.com//node/45322588" target="_blank" rel="noreferrer noopener">analysts revised the price forecast</a>.</li>
<li>FNF Group of Fidelity National Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNF#NYSE">FNF</a>) stock declined 10.98% after the company <a href="https://www.benzinga.com//node/45266700" target="_blank" rel="noreferrer noopener">reported first-quarter results</a>.</li>
<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) stock fell 10.81% last week in reaction to an executive order from the Trump administration to boost <a href="https://www.benzinga.com//node/45233995" target="_blank" rel="noreferrer noopener">domestic drug manufacturing</a>.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) stock declined 10.57% after the company reported its<a href="https://www.benzinga.com//node/45300096" target="_blank" rel="noreferrer noopener"> first-quarter financial results</a>. Analysts revised the stock&#8217;s price forecast.</li>
<li>DoorDash, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) shares decreased 10.52% after announcing downbeat first-quarter sales, and <a href="https://www.benzinga.com//node/45264549" target="_blank" rel="noreferrer noopener">analysts revised the price forecast</a>.</li>
</ol>
Photo by Jonathan Weiss via Shutterstock

AFRM

ARGX

BNTX

DASH

MMYT

SMMT

VRTX

Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?

Press Releases

STAAR Surgical Announces Changes to Board of Directors

Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly's Gene Therapy Division, and Announces ASGCT Joint Presentation on Self-Inactivating AAV Technology for Neurological and Neuromuscular Disorders

Commodity Supercycle Spotlight: Power Metallic (TSXV: PNPN | OTCQB: PNPNF) Expands High-Grade Copper-Gold Zone-More Stocks Under $2 Gaining Traction

Lilly reports first-quarter 2025 financial results and highlights pipeline momentum

Lilly to participate in Bank of America Securities 2025 Healthcare Conference

Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail Therapeutics, a Part of Lilly's Gene Therapy Division

Dividends

Lilly declares second-quarter 2025 dividend

Lilly announces transitions in executive leadership

Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation

Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine

BAYRY

CRVL

JFBR

MDRX

PNPNF

QSII

STAA

TSXV:PNPN

TSXV:PTFY

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Comments

Eli Lilly

Vendite allo scoperto

Eli Lilly (NYSE:LLY) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO